Clinical Trial Update: A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study [Phase 3]

View source ↗

Summary

Phase 3 China extension study evaluating pembrolizumab added to carboplatin-paclitaxel or nab-paclitaxel as first-line therapy for metastatic squamous non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (Abraxane) (nab-paclitaxel)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-10-20